MAGE A4-Targeted TCR Cells for Gastroesophageal Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for gastroesophageal cancer, particularly those involving chemotherapy and radiation, often result in poor prognosis due to low early detection rates and high toxicity, with limited effective options for intermediate or late-stage cancers.

Innovation Solution

Administration of modified immunoresponsive cells expressing a heterologous T-cell receptor (TCR) or chimeric antigen receptor (CAR) that specifically binds to the MAGE A4 antigenic peptide GVYDGREHTV, targeting cancer cells and minimizing systemic toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy and radiation therapy are used to treat gastroesophageal cancer, then treatment coverage is provided, but toxicity and side effects increase significantly

Engineering Contradiction:

Improvetreatment efficacyVSAvoidsystemic toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses MAGE A4 antigen as an intermediary target that is specifically expressed on cancer cells but not on normal cells. The engineered T-cells are designed to recognize and bind to this specific antigen, allowing the immune system to selectively attack cancer cells while sparing healthy tissue, thereby reducing systemic toxicity while maintaining treatment efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The treatment achieves local specificity by engineering T-cells with TCRs or CARs that recognize MAGE A4 antigen only on cancer cells. This creates a localized therapeutic effect at the tumor site without affecting other organs and tissues, reducing systemic side effects while maintaining reliable cancer cell destruction

Inventive Principle:

Principle #3Local quality

2Reliability

If early detection methods are not implemented, then treatment options are limited, but poor prognosis results

Engineering Contradiction:

ImproveprognosisVSAvoiddetection delay

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent enables preliminary identification of cancer cells through their expression of MAGE A4 antigen, which can be detected before symptoms appear or disease progresses to advanced stages. This early detection capability allows for timely intervention with immunotherapy, improving prognosis by treating cancer at an earlier, more treatable stage

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If conventional treatment methods are used for intermediate or late-stage cancer, then treatment options are available, but effectiveness is limited

Engineering Contradiction:

Improvetreatment optionsVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent fundamentally changes the therapeutic parameter from non-specific chemotherapy/radiation to highly specific T-cell immunotherapy targeting MAGE A4. This parameter change enables effective treatment of intermediate and late-stage cancers by precisely eliminating cancer cells regardless of disease stage, overcoming the limitations of conventional treatments through enhanced specificity and potency

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230190802A1Method of treatment of cancer or tumour

Publication Date: 2023.06.22 USWM CT LLC

AI summary

The present invention relates to a method of treating, preventing or delaying the progression of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of modified immunoresponsive cells expressing or presenting a heterologous T-cell receptor (TCR) having the property of binding to MAGE A4